Cilengitide is the first novel tumor-targeted therapeutic drug developed by Merck and belongs to the integrin inhibitor category. Integrins are receptors located on the cell surface that can regulate the abnormal state of various tumor cells, thereby promoting tumor growth, survival, and infiltration. Additionally, integrins play a significant role in tumor angiogenesis.
Usage
Preclinical studies have demonstrated that cilengitide, either alone or in combination with other drugs, can prevent the growth, invasion, and metastasis of gliomas.
Efficacy and Function
Cilengitide can prevent the binding of integrins to the extracellular matrix, thereby inhibiting integrin-mediated signal transduction. This drug demonstrates anti-tumor effects by blocking cell proliferation, survival and migration, and inducing apoptosis of endothelial cells. In early studies on glioma, Cilengitide, when combined with traditional drugs and chemotherapy, achieved encouraging results and showed good safety, making it a promising new treatment for various tumors.CAS No.: 188968-51-6
Number of amino acids: 5
Molecular formula: C27H40N8O7
Average molecular weight: 588.6
Exact molecular weight: 588.3
Isoelectric point (PI): 6.34
Net charge at pH 7.0: -0.02
Post time: 2025-08-08